Plus therapeutics announces dsmb approval to proceed into eighth cohort in respect™ glioblastoma trial

Austin, texas, june 16, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the data and safety monitoring board recommended the company proceed to the eighth cohort of the phase 1 dose escalation respect™ trial, which is evaluating the company's lead investigational drug, rhenium nanoliposome (rnl™), in patients with recurrent glioblastoma (gbm).
pstv Ratings Summary
pstv Quant Ranking